{"id":"https://openalex.org/W3193772661","doi":"https://doi.org/10.1016/j.jaad.2021.06.463","title":"26654 Ixekizumab demonstrates greater medication adherence, persistence, and longer monotherapy duration than secukinumab, adalimumab, ustekinumab, and etanercept up to 3 years in the treatment of psoriasis: Real-world results","display_name":"26654 Ixekizumab demonstrates greater medication adherence, persistence, and longer monotherapy duration than secukinumab, adalimumab, ustekinumab, and etanercept up to 3 years in the treatment of psoriasis: Real-world results","publication_year":2021,"publication_date":"2021-08-07","ids":{"openalex":"https://openalex.org/W3193772661","doi":"https://doi.org/10.1016/j.jaad.2021.06.463","mag":"3193772661"},"language":"en","primary_location":{"id":"doi:10.1016/j.jaad.2021.06.463","doi":"https://doi.org/10.1016/j.jaad.2021.06.463","is_oa":false,"landing_page_url":"https://doi.org/10.1016/j.jaad.2021.06.463","pdf_url":null,"source":{"id":"https://openalex.org/S58727509","display_name":"Journal of the American Academy of Dermatology","issn_l":"0190-9622","issn":["0190-9622","1097-6787"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-2","ki-jl-3","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of the American Academy of Dermatology","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5080237247","display_name":"Andrew Blauvelt","orcid":"https://orcid.org/0000-0002-2633-985X","observed_orcids":["https://orcid.org/0000-0002-2633-985X"]},"institutions":[{"id":"https://openalex.org/I4210127914","display_name":"Oregon Medical Research Center","ror":"https://ror.org/03m027021","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210127914"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Andrew Blauvelt","raw_affiliation_strings":["Oregon Medical Research Center,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Oregon Medical Research Center,","institution_ids":["https://openalex.org/I4210127914"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5057319160","display_name":"Baojin Zhu","orcid":"https://orcid.org/0000-0003-4462-1856","observed_orcids":["https://orcid.org/0000-0003-4462-1856"]},"institutions":[{"id":"https://openalex.org/I168537998","display_name":"Eli Lilly (United States)","ror":"https://ror.org/01qat3289","country_code":"US","type":"company","lineage":["https://openalex.org/I168537998"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Baojin Zhu","raw_affiliation_strings":["Eli Lilly and Company, Indianapolis, IN"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Eli Lilly and Company, Indianapolis, IN","institution_ids":["https://openalex.org/I168537998"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5060348893","display_name":"Mwangi J. Murage","orcid":"https://orcid.org/0000-0003-2769-3188","observed_orcids":["https://orcid.org/0000-0003-2769-3188"]},"institutions":[{"id":"https://openalex.org/I168537998","display_name":"Eli Lilly (United States)","ror":"https://ror.org/01qat3289","country_code":"US","type":"company","lineage":["https://openalex.org/I168537998"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Mwangi Murage","raw_affiliation_strings":["Eli Lilly and Company, Indianapolis, IN"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Eli Lilly and Company, Indianapolis, IN","institution_ids":["https://openalex.org/I168537998"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5101943354","display_name":"Jiaying Guo","orcid":"https://orcid.org/0009-0006-5744-3867","observed_orcids":["https://orcid.org/0009-0006-5744-3867"]},"institutions":[{"id":"https://openalex.org/I168537998","display_name":"Eli Lilly (United States)","ror":"https://ror.org/01qat3289","country_code":"US","type":"company","lineage":["https://openalex.org/I168537998"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Jiaying Guo","raw_affiliation_strings":["Eli Lilly and Company, Indianapolis, IN"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Eli Lilly and Company, Indianapolis, IN","institution_ids":["https://openalex.org/I168537998"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5068529059","display_name":"Terri Ridenour","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I168537998","display_name":"Eli Lilly (United States)","ror":"https://ror.org/01qat3289","country_code":"US","type":"company","lineage":["https://openalex.org/I168537998"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Terri Ridenour","raw_affiliation_strings":["Eli Lilly and Company, Indianapolis, IN"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Eli Lilly and Company, Indianapolis, IN","institution_ids":["https://openalex.org/I168537998"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5035716528","display_name":"Mingyang Shan","orcid":"https://orcid.org/0000-0002-7131-562X","observed_orcids":["https://orcid.org/0000-0002-7131-562X","https://orcid.org/0009-0009-8831-4920"]},"institutions":[{"id":"https://openalex.org/I168537998","display_name":"Eli Lilly (United States)","ror":"https://ror.org/01qat3289","country_code":"US","type":"company","lineage":["https://openalex.org/I168537998"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Mingyang Shan","raw_affiliation_strings":["Eli Lilly and Company, Indianapolis, IN"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Eli Lilly and Company, Indianapolis, IN","institution_ids":["https://openalex.org/I168537998"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5001431413","display_name":"Russel Thomas Burge","orcid":"https://orcid.org/0000-0001-7907-6400","observed_orcids":["https://orcid.org/0000-0001-7907-6400"]},"institutions":[{"id":"https://openalex.org/I168537998","display_name":"Eli Lilly (United States)","ror":"https://ror.org/01qat3289","country_code":"US","type":"company","lineage":["https://openalex.org/I168537998"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Russel Burge","raw_affiliation_strings":["Eli Lilly and Company, Indianapolis, IN"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Eli Lilly and Company, Indianapolis, IN","institution_ids":["https://openalex.org/I168537998"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":2,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":{"value":3700,"currency":"USD","value_usd":3700},"apc_paid":null,"fwci":0.1827,"has_fulltext":false,"cited_by_count":2,"citation_normalized_percentile":{"value":0.36362927,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":88,"max":93},"biblio":{"volume":"85","issue":"3","first_page":"AB111","last_page":"AB111"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10469","display_name":"Psoriasis: Treatment and Pathogenesis","score":0.9961000084877014,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T10469","display_name":"Psoriasis: Treatment and Pathogenesis","score":0.9961000084877014,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10837","display_name":"Dermatology and Skin Diseases","score":0.000699999975040555,"subfield":{"id":"https://openalex.org/subfields/2708","display_name":"Dermatology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11620","display_name":"Medication Adherence and Compliance","score":0.0003000000142492354,"subfield":{"id":"https://openalex.org/subfields/2714","display_name":"Family Practice"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/ixekizumab","display_name":"ixekizumab","score":0.9940000176429749},{"id":"https://openalex.org/keywords/secukinumab","display_name":"secukinumab","score":0.9890000224113464},{"id":"https://openalex.org/keywords/adalimumab","display_name":"adalimumab","score":0.9950000047683716},{"id":"https://openalex.org/keywords/ustekinumab","display_name":"ustekinumab","score":1.0},{"id":"https://openalex.org/keywords/etanercept","display_name":"etanercept","score":1.0},{"id":"https://openalex.org/keywords/psoriasis","display_name":"psoriasis","score":0.9909999966621399},{"id":"https://openalex.org/keywords/treatment-adherence","display_name":"medication adherence","score":0.8740000128746033},{"id":"https://openalex.org/keywords/medication-persistence","display_name":"treatment persistence","score":0.9240000247955322},{"id":"https://openalex.org/keywords/il-17a-inhibitor","display_name":"IL-17A inhibitor","score":0.8849999904632568},{"id":"https://openalex.org/keywords/tnf-alpha-inhibitors","display_name":"TNF-alpha inhibitors","score":0.8320000171661377},{"id":"https://openalex.org/keywords/real-world-evidence","display_name":"real-world evidence","score":0.4970000088214874}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.9675636291503906},{"id":"https://openalex.org/C2779786854","wikidata":"https://www.wikidata.org/wiki/Q7444755","display_name":"Secukinumab","level":4,"score":0.9580602645874023},{"id":"https://openalex.org/C2778975655","wikidata":"https://www.wikidata.org/wiki/Q420305","display_name":"Ustekinumab","level":4,"score":0.9385429620742798},{"id":"https://openalex.org/C2779745271","wikidata":"https://www.wikidata.org/wiki/Q13574436","display_name":"Ixekizumab","level":5,"score":0.9148848056793213},{"id":"https://openalex.org/C2777226972","wikidata":"https://www.wikidata.org/wiki/Q415343","display_name":"Etanercept","level":3,"score":0.8027424216270447},{"id":"https://openalex.org/C2780132546","wikidata":"https://www.wikidata.org/wiki/Q348260","display_name":"Adalimumab","level":3,"score":0.7790048122406006},{"id":"https://openalex.org/C2780564577","wikidata":"https://www.wikidata.org/wiki/Q179945","display_name":"Psoriasis","level":2,"score":0.5055572986602783},{"id":"https://openalex.org/C16005928","wikidata":"https://www.wikidata.org/wiki/Q171171","display_name":"Dermatology","level":1,"score":0.48787379264831543},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.24678996205329895},{"id":"https://openalex.org/C17991360","wikidata":"https://www.wikidata.org/wiki/Q21173843","display_name":"Tumor necrosis factor alpha","level":2,"score":0.22518140077590942},{"id":"https://openalex.org/C2776260265","wikidata":"https://www.wikidata.org/wiki/Q511097","display_name":"Psoriatic arthritis","level":3,"score":0.1939496099948883}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1016/j.jaad.2021.06.463","doi":"https://doi.org/10.1016/j.jaad.2021.06.463","is_oa":false,"landing_page_url":"https://doi.org/10.1016/j.jaad.2021.06.463","pdf_url":null,"source":{"id":"https://openalex.org/S58727509","display_name":"Journal of the American Academy of Dermatology","issn_l":"0190-9622","issn":["0190-9622","1097-6787"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-2","ki-jl-3","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of the American Academy of Dermatology","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"score":0.98580002784729,"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being"}],"study_designs":[{"id":"https://openalex.org/study-designs/observational-study","display_name":"Observational Study"}],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W3182188409","https://openalex.org/W2988907058","https://openalex.org/W3109467128","https://openalex.org/W2568456313","https://openalex.org/W4214515549","https://openalex.org/W4280578306","https://openalex.org/W3009701967","https://openalex.org/W4223599202","https://openalex.org/W3110432882","https://openalex.org/W3194237911"],"abstract_inverted_index":null,"counts_by_year":[{"year":2024,"cited_by_count":1},{"year":2023,"cited_by_count":1}],"updated_date":"2026-11-12T12:28:57.059296","created_date":"2021-08-30T00:00:00"}